## Umberto Cillo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3501457/publications.pdf

Version: 2024-02-01

485 papers 16,463 citations

20797 60 h-index 109 g-index

496 all docs 496 docs citations

496 times ranked

14221 citing authors

#	Article	IF	CITATIONS
1	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncology, The, 2009, 10, 35-43.	5.1	1,920
2	Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness. American Journal of Gastroenterology, 2008, 103, 914-921.	0.2	429
3	Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of Hepatology, 2006, 44, 723-731.	1.8	378
4	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma. Transplantation, 2016, 100, 116-125.	0.5	339
5	Liver Transplantation for the Treatment of Moderately or Well-Differentiated Hepatocellular Carcinoma. Annals of Surgery, 2004, 239, 150-159.	2.1	289
6	Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis. Liver International, 2012, 32, 919-927.	1.9	284
7	Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features. Hepatology, 2007, 45, 223-229.	3.6	282
8	Improvement in Perioperative and Long-term Outcome After Surgical Treatment of Hilar Cholangiocarcinoma. Archives of Surgery, 2012, 147, 26.	2.3	225
9	Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology, 2016, 63, 983-992.	3.6	225
10	Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut, 2016, 65, 861-869.	6.1	207
11	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut, 2019, 68, 1065-1075.	6.1	195
12	Surgery for cholangiocarcinoma. Liver International, 2019, 39, 143-155.	1.9	192
13	The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial. Hepatology, 2016, 63, 1299-1309.	3.6	186
14	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. Journal of Hepatology, 2015, 62, 617-624.	1.8	184
15	Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. Journal of Hepatology, 2017, 66, 552-559.	1.8	166
16	A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a "Blended Principle Model― American Journal of Transplantation, 2015, 15, 2552-2561.	2.6	164
17	The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. Journal of Hepatology, 2004, 40, 124-131.	1.8	161
18	Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 712-723.	0.4	155

#	Article	IF	CITATIONS
19	Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders. Liver Transplantation, 2005, 11, 1056-1063.	1.3	149
20	A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer, 2010, 10, 190.	1.1	146
21	Adherence in liver transplant recipients. Liver Transplantation, 2011, 17, 760-770.	1.3	138
22	Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncology, The, 2011, 12, 654-662.	5.1	135
23	Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study. Liver Transplantation, 2007, 13, 733-740.	1.3	124
24	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Medicine, 2016, 13, e1002006.	3.9	113
25	Intention-to-Treat Analysis of Liver Transplantation in Selected, Aggressively Treated HCC Patients Exceeding the Milan Criteria. American Journal of Transplantation, 2007, 7, 972-981.	2.6	111
26	Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. Hepatology, 2020, 72, 2206-2218.	3.6	107
27	Split and whole liver transplantation outcomes: A comparative cohort study. Liver Transplantation, 2006, 12, 402-410.	1.3	106
28	Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transplantation, 2009, 15, 1278-1287.	1.3	105
29	Influence of steroids on HCV recurrence after liver transplantation: A prospective study. Journal of Hepatology, 2007, 47, 793-798.	1.8	104
30	Subnormothermic machine perfusion protects steatotic livers against preservation injury: A potential for donor pool increase?. Liver Transplantation, 2009, 15, 20-29.	1.3	101
31	Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study. Journal of Hepatology, 2016, 65, 280-288.	1.8	98
32	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). Journal of Hepatology, 2021, 75, 610-622.	1.8	96
33	Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety. Hepatology, 2010, 51, 165-173.	3.6	93
34	12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transplantation, 2006, 12, 1464-1472.	1.3	92
35	Intentionâ€toâ€treat survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology, 2017, 66, 1910-1919.	3.6	91
36	Histological features after liver transplantation in alcoholic cirrhotics. Journal of Hepatology, 2001, 34, 716-722.	1.8	90

#	Article	IF	Citations
37	A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. Journal of Hepatology, 2014, 60, 290-297.	1.8	89
38	Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D-MELD With Particular Reference to HCV Recipients. American Journal of Transplantation, 2011, 11, 2724-2736.	2.6	86
39	mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. Annals of Surgery, 2020, 272, 855-862.	2.1	85
40	Mortality in liver transplant recipients with portal vein thrombosis - an updated meta-analysis. Transplant International, 2018, 31, 1318-1329.	0.8	84
41	Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology, 2011, 54, 890-899.	3.6	82
42	A multicenter pilot prospective study comparing Celsior and University of Wisconsin preserving solutions for use in liver transplantation. Liver Transplantation, 2003, 9, 814-821.	1.3	81
43	Perioperative thrombotic complications in liver transplantation. World Journal of Gastroenterology, 2015, 21, 8004.	1.4	81
44	Long-Term Follow-Up and Outcome of Liver Transplantation From Anti-Hepatitis C Virus-Positive Donors: A European Multicentric Case-Control Study. Transplantation, 2011, 91, 1265-1272.	0.5	79
45	Laparoscopic treatment of simple hepatic cysts and polycystic liver disease. Surgical Endoscopy and Other Interventional Techniques, 2003, 17, 623-626.	1.3	75
46	Harm and Benefits of Primary Liver Resection and Salvage Transplantation for Hepatocellular Carcinoma. American Journal of Transplantation, 2010, 10, 619-627.	2.6	73
47	Assessment of Textbook Outcome in Laparoscopic and Open Liver Surgery. JAMA Surgery, 2021, 156, e212064.	2.2	73
48	Squamous cell carcinoma antigen in human liver carcinogenesis. Journal of Clinical Pathology, 2008, 61, 445-447.	1.0	72
49	Neurological complications after orthotopic liver transplantation. Digestive and Liver Disease, 2007, 39, 740-747.	0.4	71
50	Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Alimentary Pharmacology and Therapeutics, 2006, 23, 75-84.	1.9	70
51	From Inflammation to Cancer in Inflammatory Bowel Disease: Molecular Perspectives. Anticancer Research, 2016, 36, 1447-60.	0.5	70
52	Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor–recipient matching. Digestive and Liver Disease, 2011, 43, 155-164.	0.4	69
53	When to perform hepatic resection for intermediateâ€stage hepatocellular carcinoma. Hepatology, 2015, 61, 905-914.	3.6	69
54	Nonadherent Behaviors After Solid Organ Transplantation. Transplantation Proceedings, 2011, 43, 318-323.	0.3	68

#	Article	IF	Citations
55	Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Retransplant. JAMA Surgery, 2020, 155, e204095.	2.2	67
56	Response to Therapy as a Criterion for Awarding Priority to Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Annals of Surgical Oncology, 2010, 17, 2290-2302.	0.7	66
57	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Digestive and Liver Disease, 2017, 49, 440-445.	0.4	66
58	Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut, 2002, 50, 697-700.	6.1	65
59	Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients. Clinical Infectious Diseases, 2015, 60, 997-1006.	2.9	64
60	A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transplantation, 2007, 13, 1272-1278.	1.3	63
61	Cognitive impairment and electroencephalographic alterations before and after liver transplantation: What is reversible?. Liver Transplantation, 2014, 20, 977-986.	1.3	63
62	Human Papilloma Virus Infection and Cervical Intraepithelial Neoplasia in Transplanted Patients. Transplantation Proceedings, 2008, 40, 1877-1880.	0.3	62
63	Neurocognitive-neurological complications of liver transplantation: a review. Metabolic Brain Disease, 2010, 25, 115-124.	1.4	62
64	Precision medicine in cholangiocarcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 40-40.	1.5	61
65	How to Preserve Liver Grafts From Circulatory Death With Long Warm Ischemia? A Retrospective Italian Cohort Study With Normothermic Regional Perfusion and Hypothermic Oxygenated Perfusion. Transplantation, 2021, 105, 2385-2396.	0.5	61
66	Ovarian metastasis from colorectal cancer: Prognostic value of radical oophorectomy. Journal of Surgical Oncology, 2007, 96, 113-117.	0.8	59
67	Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Digestive and Liver Disease, 2010, 42, 55-60.	0.4	59
68	Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. Hepatology International, 2013, 7, 1050-1057.	1.9	59
69	Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells. Oncotarget, 2015, 6, 2206-2221.	0.8	59
70	A COMPARATIVE PROSPECTIVE STUDY OF TWO AVAILABLE SOLUTIONS FOR KIDNEY AND LIVER PRESERVATION. Transplantation, 2004, 77, 1540-1545.	0.5	58
71	Systemic administration of a novel human umbilical cord mesenchymal stem cells population accelerates the resolution of acute liver injury. BMC Gastroenterology, 2012, 12, 88.	0.8	58
72	SERPINB3 is associated with TGF- $\hat{l}^21$ and cytoplasmic $\hat{l}^2$ -catenin expression in hepatocellular carcinomas with poor prognosis. British Journal of Cancer, 2014, 110, 2708-2715.	2.9	57

#	Article	IF	Citations
73	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database. Gut, 2023, 72, 141-152.	6.1	57
74	Importance of primary indication and liver function between stages: results of a multicenter Italian audit of ALPPS 2012–2014. Hpb, 2016, 18, 419-427.	0.1	56
75	Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. JCO Precision Oncology, 2021, 5, 1166-1177.	1.5	55
76	Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma. BMC Cancer, 2012, 12, 177.	1.1	54
77	Use of $\langle i \rangle N \langle i \rangle$ -acetylcysteine during liver procurement: A prospective randomized controlled study. Liver Transplantation, 2013, 19, 135-144.	1.3	54
78	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. European Journal of Cancer, 2017, 73, 74-84.	1.3	54
79	Use of Everolimus in Liver Transplantation. Transplantation, 2017, 101, 239-251.	0.5	54
80	A Prospective Policy Development to Increase Split-Liver Transplantation for 2 Adult Recipients. Annals of Surgery, 2014, 259, 157-165.	2.1	53
81	Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome. Hepatology, 2021, 73, 1909-1919.	<b>3.</b> 6	53
82	ALPPS for Locally Advanced Intrahepatic Cholangiocarcinoma: Did Aggressive Surgery Lead to the Oncological Benefit? An International Multi-center Study. Annals of Surgical Oncology, 2020, 27, 1372-1384.	0.7	53
83	Diffusion, outcomes and implementation of minimally invasive liver surgery: a snapshot from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry. Updates in Surgery, 2017, 69, 271-283.	0.9	52
84	A national mandatory-split liver policy: A report from the Italian experience. American Journal of Transplantation, 2019, 19, 2029-2043.	2.6	52
85	Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?. European Journal of Surgical Oncology, 2008, 34, 256-262.	0.5	51
86	Validation of the BCLC Prognostic System in Surgical Hepatocellular Cancer Patients. Transplantation Proceedings, 2009, 41, 1260-1263.	0.3	51
87	Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma. Cancer, 2011, 117, 125-133.	2.0	51
88	Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on $\hat{a} \in \mathbb{R}$ mumber of patients needed to transplanta $\hat{a} \in \mathbb{R}$ measure of transplant benefit. Journal of Hepatology, 2014, 60, 1165-1171.	1.8	50
89	Covert hepatic encephalopathy: Agreement and predictive validity of different indices. World Journal of Gastroenterology, 2014, 20, 15756.	1.4	50
90	Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma. BMC Gastroenterology, 2012, 12, 118.	0.8	49

#	Article	IF	CITATIONS
91	Sexual Dysfunction in Chronic Liver Disease: Is Liver Transplantation an Effective Cure?. Transplantation, 2010, 89, 1425-1429.	0.5	48
92	Defining the possible therapeutic benefit of lymphadenectomy among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2016, 113, 685-691.	0.8	48
93	Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transplantation, 2007, 13, 343-348.	1.3	47
94	Italian experience in minimally invasive liver surgery: a national survey. Updates in Surgery, 2015, 67, 129-140.	0.9	47
95	Characterisation of the immune-related transcriptome in resected biliary tract cancers. European Journal of Cancer, 2017, 86, 158-165.	1.3	47
96	De Novo Tumors Are a Major Cause of Late Mortality After Orthotopic Liver Transplantation. Transplantation Proceedings, 2009, 41, 1303-1305.	0.3	46
97	Human liver autofluorescence: An intrinsic tissue parameter discriminating normal and diseased conditions. Lasers in Surgery and Medicine, 2010, 42, 371-378.	1.1	46
98	Assessment of alcohol consumption in liver transplant candidates and recipients: The best combination of the tools available. Liver Transplantation, 2014, 20, 815-822.	1.3	46
99	Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virusâ€"infected patients treated with directâ€acting antivirals. Liver Transplantation, 2017, 23, 1103-1112.	1.3	46
100	Torque Teno virus: any pathological role in liver transplanted patients?. Transplant International, 2008, 21, 972-979.	0.8	45
101	Diagnostic and prognostic role of <scp>SCCA</scp> â€ <scp>lgM</scp> serum levels in hepatocellular carcinoma ( <scp>HCC</scp> ). Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1637-1644.	1.4	44
102	Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion $\hat{a} \in \hat{c}$ a multi $\hat{a} \in \hat{c}$ enter retrospective cohort study. Transplant International, 2020, 33, 567-575.	0.8	44
103	Survival Benefit of Liver Transplantation Versus Resection for Hepatocellular Carcinoma: Impact of MELD Score. Annals of Surgical Oncology, 2015, 22, 1901-1907.	0.7	43
104	Colonization and infection due to carbapenemase-producing Enterobacteriaceae in liver and lung transplant recipients and donor-derived transmission: a prospective cohort study conducted in Italy. Clinical Microbiology and Infection, 2019, 25, 203-209.	2.8	43
105	The survival benefit of liver transplantation in hepatocellular carcinoma patients. Digestive and Liver Disease, 2010, 42, 642-649.	0.4	42
106	Machine perfusion at $20 \hat{A}^{\circ}$ C reduces preservation damage to livers from non-heart beating donors. Cryobiology, 2011, 62, 152-158.	0.3	42
107	Subnormothermic Machine Perfusion for Non–Heart-Beating Donor Liver Grafts Preservation in a Swine Model: A New Strategy to Increase the Donor Pool?. Transplantation Proceedings, 2012, 44, 2026-2028.	0.3	42
108	Surgery and Hepatocellular Carcinoma. Liver Cancer, 2017, 6, 44-50.	4.2	42

#	Article	IF	CITATIONS
109	Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transplantation, 2009, 15, 619-628.	1.3	41
110	BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20â€year survey by the Italian Liver Cancer group. Liver International, 2015, 35, 223-231.	1.9	41
111	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. Digestive and Liver Disease, 2018, 50, 1105-1114.	0.4	41
112	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. Liver International, 2019, 39, 1478-1489.	1.9	41
113	Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis. Thrombosis and Haemostasis, 2020, 120, 1173-1181.	1.8	41
114	Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: A new exception to MELD score in the allocation system to liver transplantation?. Journal of Hepatology, 2011, 55, 491-496.	1.8	40
115	Risk Factors for Central Pontine and Extrapontine Myelinolysis After Liver Transplantation. Transplantation, 2015, 99, 1257-1264.	0.5	40
116	Prognostic Benefit of the Addition of a Quantitative Index of Hepatic Encephalopathy to the MELD score: the MELDâ€EG. Liver International, 2015, 35, 58-64.	1.9	40
117	Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. Journal of Vascular and Interventional Radiology, 2017, 28, 1495-1502.	0.2	40
118	Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver) Tj ETQq0 0 0 rgE	BT /Deverlo	ck <b>40</b> Tf 50 37
119	Feasibility and Limits of Split Liver Transplantation From Pediatric Donors. Annals of Surgery, 2006, 244, 805-814.	2.1	39
120	Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure. Clinical Gastroenterology and Hepatology, 2020, 18, 1188-1196.e3.	2.4	39
121	Correlation between the liver temperature employed during machine perfusion and reperfusion damage: Role of Ca2+. Liver Transplantation, 2008, 14, 494-503.	1.3	38
122	Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. Oncoscience, 2015, 2, 443-456.	0.9	38
123	Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. Clinical Transplantation, 2019, 33, e13666.	0.8	38
124	Microbiologic Contamination of Intraoperative Blood Salvaged During Liver Transplantation. Transplantation Proceedings, 2007, 39, 1889-1891.	0.3	37
125	Outcomes of enhanced one-stage ultrasound-guided hepatectomy for bilobar colorectal liver metastases compared to those of ALPPS: a multicenter case-match analysis. Hpb, 2019, 21, 1411-1418.	0.1	37
126	Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. Hepatology International, 2020, 14, 930-943.	1.9	37

#	Article	IF	CITATIONS
127	Features predicting unresectability in hepatoblastoma. Cancer, 2007, 110, 1050-1058.	2.0	36
128	Nifedipine versus carvedilol in the treatment of <i>de novo </i> arterial hypertension after liver transplantation: Results of a controlled clinical trial. Liver Transplantation, 2008, 14, 1020-1028.	1.3	36
129	Full-Right-Full-Left Split Liver Transplantation: The Retrospective Analysis of an Early Multicenter Experience Including Graft Sharing. American Journal of Transplantation, 2012, 12, 2198-2210.	2.6	36
130	Laparoscopic microwave ablation in patients with hepatocellular carcinoma: a prospective cohort study. Hpb, 2014, 16, 979-986.	0.1	36
131	Laparoscopic Microwave Ablation and Portal Vein Ligation for Staged Hepatectomy (LAPS). Annals of Surgery, 2015, 261, e42-e43.	2.1	36
132	Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World Journal of Gastroenterology, 2016, 22, 232.	1.4	35
133	A Regenerative Approach with Dermal Micrografts in the Treatment of Chronic Ulcers. Stem Cell Reviews and Reports, 2017, 13, 139-148.	5.6	35
134	Multifocal hepatoblastoma: Is there a place for partial hepatectomy?. Medical and Pediatric Oncology, 2003, 40, 113-117.	1.0	34
135	Skin Cancer and Other Cutaneous Disorders in Liver Transplant Recipients. Acta Dermato-Venereologica, 2012, 92, 411-415.	0.6	34
136	Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit. Hepatology, 2017, 65, 1741-1748.	3.6	34
137	Long-Term Outcomes in Liver Transplant Patients With Hepatic C Infection Receiving Tacrolimus or Cyclosporine. Transplantation Proceedings, 2006, 38, 2964-2967.	0.3	33
138	Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa). World Journal of Surgical Oncology, 2014, 12, 46.	0.8	33
139	Fifteen years and 382 extended right grafts from in situ split livers in a multicenter study: Are these still extended criteria liver grafts?. Liver Transplantation, 2015, 21, 500-511.	1.3	33
140	Totally Laparoscopic Microwave Ablation and Portal Vein Ligation for Staged Hepatectomy. Annals of Surgical Oncology, 2015, 22, 2787-2788.	0.7	33
141	The Italian Consensus on minimally invasive simultaneous resections for synchronous liver metastasis and primary colorectal cancer: A Delphi methodology. Updates in Surgery, 2021, 73, 1247-1265.	0.9	33
142	Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. Clinica Chimica Acta, 2004, 347, 129-138.	0.5	32
143	Complications of radiofrequency thermal ablation in hepatocellular carcinoma: what about "explosive" spread?. Gut, 2006, 55, 435-436.	6.1	32
144	Subnormothermic Machine Perfusion Protects Against Rat Liver Preservation Injury: A Comparative Evaluation With Conventional Cold Storage. Transplantation Proceedings, 2007, 39, 1765-1767.	0.3	32

#	Article	IF	Citations
145	Transarterial chemoembolization with DC Bead LUMIâ,,¢ radiopaque beads for primary liver cancer treatment: preliminary experience. Future Oncology, 2017, 13, 2243-2252.	1.1	32
146	Successful transplantation of an injured liver. Transplantation Proceedings, 2000, 32, 131-133.	0.3	31
147	SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity. Scientific Reports, 2016, 5, 17701.	1.6	31
148	Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study. World Journal of Gastroenterology, 2018, 24, 4403-4411.	1.4	31
149	Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. Hepatology, 2020, 71, 569-582.	3.6	30
150	Modulation of Biliary Cancer Chemoâ€Resistance Through MicroRNAâ€Mediated Rewiring of the Expansion of CD133+ Cells. Hepatology, 2020, 72, 982-996.	3.6	30
151	Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant. JAMA Surgery, 2021, 156, e213112.	2.2	30
152	Different hemodynamic patterns of alcoholic and viral endstage cirrhosis: Analysis of explanted liver weight, degree of fibrosis and splanchnic Doppler parameters. Scandinavian Journal of Gastroenterology, 2007, 42, 256-262.	0.6	29
153	Risk-adjusted benchmarks in laparoscopic liver surgery in a national cohort. British Journal of Surgery, 2020, 107, 845-853.	0.1	29
154	Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study. American Journal of Transplantation, 2022, 22, 1191-1200.	2.6	29
155	Blunt liver injury: from non-operative management to liver transplantation. Injury, 2003, 34, 181-186.	0.7	28
156	Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. Journal of Surgical Oncology, 2007, 95, 213-220.	0.8	28
157	Decreased apoptosis in fatty livers submitted to subnormothermic machine-perfusion respect to cold storage. European Journal of Histochemistry, 2011, 55, e40.	0.6	28
158	Risk Factors in Liver Retransplantation: A Single-Center Experience. Transplantation Proceedings, 2011, 43, 1110-1113.	0.3	28
159	Age and equity in liver transplantation: An organ allocation model. Liver Transplantation, 2015, 21, 1241-1249.	1.3	28
160	Transplant benefit for patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 9183.	1.4	28
161	Long-Term Outcome of Bone Mineral Density in Children who Underwent a Successful Liver Transplantation. Transplantation, 2004, 78, 899-903.	0.5	27
162	Incidental Cystadenoma After Laparoscopic Treatment of Hepatic Cysts: Which Strategy?. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2004, 14, 282-284.	0.4	27

#	Article	IF	Citations
163	Sorafenib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplantation?. Transplantation Proceedings, 2012, 44, 1989-1991.	0.3	27
164	Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial. Liver Transplantation, 2019, 25, 242-251.	1.3	27
165	Liver transplantation versus liver resection for colorectal liver metastasis: a survival benefit analysis in patients stratified according to tumor burden score. Transplant International, 2021, 34, 1722-1732.	0.8	27
166	Giant splenic epithelial cyst with elevated serum markers CEA and CA 19-9 levels: an incidental association?. Anticancer Research, 2003, 23, 773-6.	0.5	27
167	GH/IGF system, cirrhosis and liver transplantation. Clinica Chimica Acta, 2001, 310, 31-37.	0.5	26
168	Liver transplantation using suboptimal grafts: Impact of donor harvesting technique. Liver Transplantation, 2007, 13, 1444-1450.	1.3	26
169	Microwave Thermal Ablation for Hepatocarcinoma: Six Liver Transplantation Cases. Transplantation Proceedings, 2011, 43, 1091-1094.	0.3	26
170	http://www.D-MELD.com, the Italian survival calculator to optimize donor to recipient matching and to identify the unsustainable matches in liver transplantation. Transplant International, 2012, 25, 294-301.	0.8	26
171	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. Hepatology, 2018, 68, 1232-1244.	3.6	26
172	Invasive fungal infection before and after liver transplantation. World Journal of Gastroenterology, 2020, 26, 7485-7496.	1.4	26
173	Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 347-359.	1.9	25
174	Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC. Cell Death and Disease, 2019, 10, 703.	2.7	25
175	Microvascular Autonomic Dysfunction May Justify False-Positive Stress Myocardial Perfusion Imaging in Patients With Liver Cirrhosis Undergoing Liver Transplantation. Transplantation Proceedings, 2008, 40, 1916-1917.	0.3	24
176	Liver Autotransplantation for the Treatment of Unresectable Hepatic Metastasis: An Uncommon Indicationâ€"A Case Report. Transplantation Proceedings, 2012, 44, 1930-1933.	0.3	24
177	Laparoscopic Ablation of Hepatocellular Carcinoma in Cirrhotic Patients Unsuitable for Liver Resection or Percutaneous Treatment: A Cohort Study. PLoS ONE, 2013, 8, e57249.	1.1	24
178	The Intentionâ€toâ€Treat Effect of Bridging Treatments in the Setting of Milan Criteriaâ€"In Patients Waiting for Liver Transplantation. Liver Transplantation, 2019, 25, 1023-1033.	1.3	24
179	Lyn-mediated mitochondrial tyrosine phosphorylation is required to preserve mitochondrial integrity in early liver regeneration. Biochemical Journal, 2010, 425, 401-412.	1.7	23
180	Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection. Transplantation, 2016, 100, 1507-1512.	0.5	23

#	Article	IF	CITATIONS
181	Different susceptibility of liver grafts from lean and obese Zucker rats to preservation injury. Cryobiology, 2009, 59, 327-334.	0.3	22
182	Development of a Risk Prediction Model for Carbapenem-resistant <i>Enterobacteriaceae</i> Infection After Liver Transplantation: A Multinational Cohort Study. Clinical Infectious Diseases, 2021, 73, e955-e966.	2.9	22
183	Liver Retransplantation in Adults: The Largest Multicenter Italian Study. PLoS ONE, 2012, 7, e46643.	1.1	22
184	Long-term medical and psycho-social evaluation of patients undergoing orthotopic liver transplantation for alcoholic liver disease. Transplant International, 2000, 13, S174-S178.	0.8	21
185	Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Annals of Oncology, 2006, 17, v153-v157.	0.6	21
186	A matched pair analysis of multicenter longterm followâ€up after splitâ€liver transplantation with extended right grafts. Liver Transplantation, 2017, 23, 1384-1395.	1.3	21
187	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. Cancers, 2021, 13, 1150.	1.7	21
188	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers, 2021, 13, 1673.	1.7	21
189	Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?. Cancers, 2021, 13, 2274.	1.7	21
190	Liver transplantation for the management of hepatoblastoma. Transplantation Proceedings, 2003, 35, 2983-2985.	0.3	20
191	Progression of Hepatocellular Carcinoma Before Liver Transplantation: Dropout or Liver Transplantation?. Transplantation Proceedings, 2009, 41, 1264-1267.	0.3	20
192	Gender Differences in the Quality of Life of Patients with Liver Cirrhosis Related to Hepatitis C after Liver Transplantation. Blood Purification, 2013, 36, 231-236.	0.9	20
193	Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West–East Collaborative Effort. Cancers, 2020, 12, 452.	1.7	20
194	Tumor Microenvironment Versus Cancer Stem Cells in Cholangiocarcinoma: Synergistic Effects?. Journal of Cellular Physiology, 2016, 231, 768-776.	2.0	19
195	The role of adipose stem cells in inflammatory bowel disease: From biology to novel therapeutic strategies. Cancer Biology and Therapy, 2016, 17, 889-898.	1.5	19
196	Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus–related liver carcinogenesis. Translational Research, 2016, 168, 122-133.	2.2	19
197	Videolaparoscopic microwave ablation in patients with HCC at a European highâ€volume center: Results of 815 procedures. Journal of Surgical Oncology, 2019, 120, 956-965.	0.8	19
198	Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2005, 11, 6920.	1.4	19

#	Article	IF	CITATIONS
199	Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. World Journal of Gastroenterology, 2006, 12, 1706.	1.4	19
200	Adjuvant chemotherapy for transplanted hepatocellular carcinoma patients: impact on survival or HCV recurrence timing. Transplantation Proceedings, 2003, 35, 2991-2994.	0.3	18
201	Endoscopic Treatment of Bile Duct Complications After Orthotopic Liver Transplantation. Transplantation Proceedings, 2007, 39, 1942-1944.	0.3	18
202	Estimation of the Harm to the Waiting List as a Crucial Factor in the Selection of Patients With Hepatocellular Carcinoma for Liver Transplantation. Transplantation Proceedings, 2010, 42, 1194-1196.	0.3	18
203	Central Nervous System Infectious Complications Early After Liver Transplantation. Transplantation Proceedings, 2010, 42, 1216-1222.	0.3	18
204	A New Liver Autotransplantation Technique Using Subnormothermic Machine Perfusion for Organ Preservation in a Porcine Model. Transplantation Proceedings, 2011, 43, 997-1000.	0.3	18
205	A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study. Digestive and Liver Disease, 2014, 46, 340-347.	0.4	18
206	Salvage liver transplantation after laparoscopic resection for hepatocellular carcinoma: a multicenter experience. Updates in Surgery, 2015, 67, 215-222.	0.9	18
207	Psychosocial Support in Liver Transplantation: A Dyadic Study With Patients and Their Family Caregivers. Frontiers in Psychology, 2019, 10, 2304.	1.1	18
208	Multicentre evaluation of case volume in minimally invasive hepatectomy. British Journal of Surgery, 2020, 107, 443-451.	0.1	18
209	Who Fares Worse After Liver Transplantation? Impact of Donor and Recipient Variables on Outcome. Transplantation, 2013, 95, 1528-1534.	0.5	17
210	A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. Liver International, 2015, 35, 184-191.	1.9	17
211	Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Costâ€Utility Analysis. World Journal of Surgery, 2015, 39, 2500-2509.	0.8	17
212	Robotic hepatectomy and biliary reconstruction for perihilar cholangiocarcinoma: a pioneer western case series. Updates in Surgery, 2021, 73, 999-1006.	0.9	17
213	Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis. Annals of Transplantation, 2018, 23, 789-801.	0.5	17
214	Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. European Journal of Cancer, 2022, 166, 165-175.	1.3	17
215	Cystadenoma and laparoscopic surgery for hepatic cystic disease: a need for laparotomy?. Surgical Endoscopy and Other Interventional Techniques, 2005, 19, 1077-1081.	1.3	16
216	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. Hepatology Communications, 2021, 5, 1987-2000.	2.0	16

#	Article	IF	Citations
217	Growth hormone/insulin-like growth factor $1$ axis recovery after liver transplantation: A preliminary prospective study. Liver Transplantation, 2004, 10, 692-698.	1.3	15
218	Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2006, 24, 1495-1501.	1.9	15
219	Liver transplantation for hepatocellular carcinoma in clinical practice. European Journal of Gastroenterology and Hepatology, 2012, 24, 195-202.	0.8	15
220	Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection. Personalized Medicine, 2020, 17, 83-87.	0.8	15
221	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers, 2021, 13, 4882.	1.7	15
222	A Combining Method to Enhance the <i>In Vitro </i> Differentiation of Hepatic Precursor Cells. Tissue Engineering - Part C: Methods, 2010, 16, 1543-1551.	1.1	14
223	Donor-Model for End-Stage Liver Disease and Donor-Recipient Matching in Liver Transplantation. Transplantation Proceedings, 2011, 43, 974-976.	0.3	14
224	Totally laparoscopic liver resections for primary and metastatic cancer in the elderly: safety, feasibility and short-term outcomes. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 1881-1886.	1.3	14
225	The tyrosine phosphatase SHP-1 inhibits proliferation of activated hepatic stellate cells by impairing PDGF receptor signaling. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 288-298.	1.9	14
226	Biodegradable Biliary Stents for Percutaneous Treatment of Post-liver Transplantation Refractory Benign Biliary Anastomotic Strictures. CardioVascular and Interventional Radiology, 2020, 43, 749-755.	0.9	14
227	Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positive donors. World Journal of Gastroenterology, 2017, 23, 2095.	1.4	14
228	Functional and morphological graft monitoring after liver transplantation. Clinica Chimica Acta, 2001, 310, 17-23.	0.5	13
229	Liver Damage During Ischemia/Reperfusion and Glutathione: Implications for Potential Organ Donors. Transplantation Proceedings, 2007, 39, 1768-1770.	0.3	13
230	Alcohol Abuse and De Novo Tumors in Liver Transplantation. Transplantation Proceedings, 2009, 41, 1310-1312.	0.3	13
231	Extraordinary disease-free survival in a rare malignant extrarenal rhabdoid tumor: a case report and review of the literature. Journal of Medical Case Reports, 2018, 12, 39.	0.4	13
232	Risk Factors for Early Mortality in Liver Transplant Patients. Transplantation Proceedings, 2019, 51, 179-183.	0.3	13
233	The Psychosocial Assessment of Transplant Candidates: Inter-Rater Reliability and PredictiveÂValue of the Italian Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT). Psychosomatics, 2020, 61, 127-134.	2.5	13
234	A 2020 update on liver transplant for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2020, 14, 885-900.	1.4	13

#	Article	IF	CITATIONS
235	Minimally Invasive Stage 1 to Protect Against the Risk of Liver Failure: Results from the Hepatocellular Carcinoma Series of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Italian Registry. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2020, 30, 1082-1089.	0.5	13
236	Minimally invasive treatment of colorectal liver metastases: does robotic surgery provide any technical advantages over laparoscopy? A multicenter analysis from the IGoMILS (Italian Group of) Tj ETQq0 0	0 rg <b>Bī.∮</b> Ove	rlo <b>als</b> 10 Tf 50
237	Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort. Microorganisms, 2022, 10, 1021.	1.6	13
238	Split-Liver Transplantation With Pediatric Donors: A Multicenter Experience. Transplantation, 2005, 79, 1148-1153.	0.5	12
239	Prospective Validation of a New Priority Allocation Model for Liver Transplant Candidates: An Interim Analysis. Transplantation Proceedings, 2009, 41, 1092-1095.	0.3	12
240	Antiviral therapy and fibrosis progression in patients with mild–moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. Digestive and Liver Disease, 2012, 44, 603-609.	0.4	12
241	Sorafenib use in the transplant setting. Liver Transplantation, 2014, 20, 1021-1028.	1.3	12
242	Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 29-37.	1.4	12
243	L-GrAFT and EASE scores in liver transplantation: Need for reciprocal external validation and comparison with other scores. Journal of Hepatology, 2021, 75, 729-731.	1.8	12
244	CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. Transplantation Proceedings, 1991, 23, 3035-7.	0.3	12
245	Acute hepatic failure in pregnancy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2004, 112, 230-232.	0.5	11
246	Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver?s early regeneration after auxiliary partial orthotopic liver transplantation. Transplant International, 2005, 17, 713-716.	0.8	11
247	Multimodal therapy before liver transplantation for hepatocellular carcinoma. Hepatology Research, 2005, 31, 112-115.	1.8	11
248	Hepatitis C Virus–Related Cirrhosis as a Significant Mortality Factor in Intention-to-Treat Analysis in Liver Transplantation. Transplantation Proceedings, 2007, 39, 1901-1903.	0.3	11
249	Prognostic Evaluation of the Donor Risk Index Among a Prospective Cohort of Italian Patients Undergoing Liver Transplantation. Transplantation Proceedings, 2009, 41, 1096-1098.	0.3	11
250	Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients. Transplant International, 2011, 24, 276-283.	0.8	11
251	Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study. Transplant Infectious Disease, 2021, 23, e13608.	0.7	11
252	Micronuclei and broken eggs in human liver carcinogenesis. Anticancer Research, 2008, 28, 2507-11.	0.5	11

#	Article	IF	Citations
253	Successful pregnancy in a liver transplant recipient treated with lamivudine for de novo hepatitis�B in the graft. Transplant International, 2005, 17, 730-734.	0.8	10
254	Combined Liver and Kidney Transplantation: Analysis of Padova Experience. Transplantation Proceedings, 2007, 39, 1933-1935.	0.3	10
255	Intensive Care Unit Admission of Decompensated Cirrhotic Patients: Prognostic Scoring Systems. Transplantation Proceedings, 2011, 43, 1079-1084.	0.3	10
256	Can liver transplantation provide the statistical cure?. Liver Transplantation, 2014, 20, 210-217.	1.3	10
257	Utilityâ€based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alphaâ€fetoprotein model as a survival predictor. Liver Transplantation, 2015, 21, 1250-1258.	1.3	10
258	Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression. Transplantation Reviews, 2018, 32, 142-150.	1.2	10
259	Preoperative predictors of liver decompensation after mini-invasive liver resection. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 718-727.	1.3	10
260	Monofocal hepatocellular carcinoma: How much does size matter?. Liver International, 2021, 41, 396-407.	1.9	10
261	Liver resection for perihilar cholangiocarcinoma: Impact of biliary drainage failure on postoperative outcome. Results of an Italian multicenter study. Surgery, 2021, 170, 383-389.	1.0	10
262	International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. JHEP Reports, 2021, 3, 100331.	2.6	10
263	Is minimally invasive liver surgery a reasonable option in recurrent HCC? A snapshot from the I Go MILS registry. Updates in Surgery, 2022, 74, 87-96.	0.9	10
264	Effects on in vivo and in vitro hepatocyte proliferation of methylprednisolone, azathioprine, mycophenolic acid, mizoribine, and prostaglandin E1. Transplantation Proceedings, 1992, 24, 2868-71.	0.3	10
265	Comparison Between Nifedipine and Carvedilol in the Treatment of de novo Arterial Hypertension After Liver Transplantation: Preliminary Results of a Controlled Clinical Trial. Transplantation Proceedings, 2005, 37, 1245-1247.	0.3	9
266	A New Experimental Model of Isolated Perfused Pig Liver to Support Acute Hepatic Failure. Transplantation Proceedings, 2007, 39, 2028-2030.	0.3	9
267	Hepatitis C Virus Adversely Affects Quality of Life. Blood Purification, 2011, 32, 144-149.	0.9	9
268	Right Hemihepatectomy in Presence of Congenital Absence of Portal Vein Bifurcation: A Challenging but Feasible Procedure. Journal of the American College of Surgeons, 2012, 215, e1-e4.	0.2	9
269	Laparoscopic Microwave Thermal Ablation for Late Recurrence of Local Hepatocellular Carcinoma after Liver Transplant: Case Report. Progress in Transplantation, 2014, 24, 142-145.	0.4	9
270	Mesenchymal Hamartoma of the Liver in Older Children. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 667-673.	0.6	9

#	Article	IF	Citations
271	Shortâ€term outcomes of paediatric liver transplant recipients after transition to Adult Healthcare Service. Liver International, 2018, 38, 1316-1321.	1.9	9
272	Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. BMC Gastroenterology, 2020, 20, 251.	0.8	9
273	Liver transplantation for rare liver diseases and rare indications for liver transplant. Translational Gastroenterology and Hepatology, 2021, 6, 27-27.	1.5	9
274	Colon Rectal Liver Metastases: The Role of the Liver Transplantation in the Era of the Transplant Oncology and Precision Medicine. Frontiers in Surgery, 2021, 8, 693387.	0.6	9
275	Incidence and Clinical Impact of Bile Leakage after Laparoscopic and Open Liver Resection: An International Multicenter Propensity Score-Matched Study of 13,379 Patients. Journal of the American College of Surgeons, 2022, 234, 99-112.	0.2	9
276	Impact of Severe Infections on the Outcome of Major Liver Surgery: a Pathophysiologic and Clinical Analysis. Journal of Chemotherapy, 1999, 11, 513-517.	0.7	8
277	Long-Term Results of Liver Transplantation for Hepatocellular Carcinoma: An Update of the University of Padova Experience. Transplantation Proceedings, 2007, 39, 1892-1894.	0.3	8
278	Bile duct stones and casts after liver transplantation: Different entities but similar prevention strategy?. Liver Transplantation, 2008, 14, 1400-1403.	1.3	8
279	Liver Transplantation for Massive Hepatomegaly Due to Polycystic Liver Disease: An Extreme Case. Transplantation Proceedings, 2012, 44, 2038-2040.	0.3	8
280	Use of Grafts From Anti-HBc–Positive Donors in Liver Transplantation: A 5-Year, Single-Center Experience. Transplantation Proceedings, 2013, 45, 2707-2710.	0.3	8
281	Hepatic Resection for Disappearing Liver Metastasis: a Cost-Utility Analysis. Journal of Gastrointestinal Surgery, 2015, 19, 1668-1675.	0.9	8
282	Liver radiofrequency ablation as emergency treatment for a ruptured hepatocellular carcinoma: a case report. Journal of Medical Case Reports, 2017, 11, 54.	0.4	8
283	SerpinB3 induces dipeptidyl-peptidase IV/CD26 expression and its metabolic effects in hepatocellular carcinoma. Life Sciences, 2018, 200, 134-141.	2.0	8
284	Changing indications for liver transplant: slow decline of hepatitis viruses in Italy. Infectious Diseases, 2020, 52, 557-562.	1.4	8
285	Liver Transplantation for T2 Hepatocellular Carcinoma during the COVID-19 Pandemic: A Novel Model Balancing Individual Benefit against Healthcare Resources. Cancers, 2021, 13, 1416.	1.7	8
286	Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. Journal of Personalized Medicine, $2021, 11, 499$ .	1.1	8
287	Coronary artery calcium on standard chest computed tomography predicts cardiovascular events after liver transplantation. International Journal of Cardiology, 2021, 339, 219-224.	0.8	8
288	The Need to Update Endpoints and Outcome Analysis in the Rapidly Changing Field of Liver Transplantation. Transplantation, 2022, 106, 938-949.	0.5	8

#	Article	IF	CITATIONS
289	Myocardial perfusion scintigraphy in patients with liver cirrhosis evaluated for orthotopic liver transplantation. Transplantation Proceedings, 2001, 33, 1447-1448.	0.3	7
290	Is apoptosis of vascular smooth muscle cells involved in the development of Takayasu arteritis? Suggestions from a case report. British Journal of Rheumatology, 2005, 44, 484-487.	2.5	7
291	Prognostic Impact of Model for End-Stage Liver Disease Score in Patients Undergoing Liver Transplantation With Suboptimal Livers. Transplantation Proceedings, 2007, 39, 1907-1909.	0.3	7
292	Monoclonal gammopathy after liver transplantation: a risk factor for long-term medical complications other than malignancies. Transplant International, 2012, 25, 25-33.	0.8	7
293	Urgency, utility, and time horizon of transplant benefit. Liver Transplantation, 2015, 21, 565-566.	1.3	7
294	Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. Transplant International, 2015, 28, 1055-1065.	0.8	7
295	Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial. Journal of Hepatology, 2017, 66, S12-S13.	1.8	7
296	Surgical Management of Hepatic Benign Disease: Have the Number of Liver Resections Increased in the Era of Minimally Invasive Approach? Analysis from the I Go MILS (Italian Group of Minimally Invasive) Tj ETQq0 0 (	0 r <b>gΒ</b> Τ/Ον	erbock 10 Tf !
297	Pulmonary Resection for Metastasis of Hepatocellular Carcinoma Recurring After Liver Transplant: An Italian Multicenter Experience. Frontiers in Oncology, 2020, 10, 381.	1.3	7
298	The role of the comprehensive complication index for the prediction of survival after liver transplantation. Updates in Surgery, 2021, 73, 209-221.	0.9	7
299	Bile Microbiota in Liver Transplantation: Proof of Concept Using Gene Amplification in a Heterogeneous Clinical Scenario. Frontiers in Surgery, 2021, 8, 621525.	0.6	7
300	Low P66shc with High SerpinB3 Levels Favors Necroptosis and Better Survival in Hepatocellular Carcinoma. Biology, 2021, 10, 363.	1.3	7
301	Sustained Complete Response after Biological Downstaging in Patients with Hepatocellular Carcinoma: XXL-Like Prioritization for Liver Transplantation or "Wait and See―Strategy?. Cancers, 2021, 13, 2406.	1.7	7
302	Effect on the canine Eck fistula liver of intraportal TGF-beta alone or with hepatic growth factors. Hepatology, 1992, 16, 1267-70.	3.6	7
303	A prospective longitudinal assessment of <i>de novo</i> metabolic syndrome after liver transplantation. Clinical Transplantation, 2022, 36, e14532.	0.8	7
304	Long-term follow-up after liver transplantation for blunt hepatic trauma. Transplantation Proceedings, 2002, 34, 1226-1228.	0.3	6
305	Extreme marginal donor: severe hypothermia as a rare preservation condition for explantable organs—a case report. Transplantation Proceedings, 2003, 35, 1282-1284.	0.3	6
306	Syngeneic Living-Donor Liver Transplantation for Hemangioendothelioma: A Clinical Model for Studying Liver Regeneration. American Journal of Transplantation, 2005, 5, 2309-2314.	2.6	6

#	Article	IF	Citations
307	Neoadjuvant Therapy Protocol and Liver Transplantation in Combination With Pancreatoduodenectomy for the Treatment of Hilar Cholangiocarcinoma Occurring in a Case of Primary Sclerosing Cholangitis: Case Report With a More Than 8-Year Disease-Free Survival. Transplantation Proceedings, 2011, 43, 1187-1189.	0.3	6
308	Model for end-stage liver disease-sodium and survival benefit in liver transplantation. Transplant International, 2013, 26, 138-144.	0.8	6
309	Early markers of neural dysfunction and compensation: A model from minimal hepatic encephalopathy. Clinical Neurophysiology, 2014, 125, 1138-1144.	0.7	6
310	Antibiotic prophylaxis for preventing postorthotopic liver transplant tuberculosis: is there a safe alternative to isoniazid? Transplant International, 2017, 30, 734-736.	0.8	6
311	Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF. Journal of Hepatology, 2019, 70, 801-803.	1.8	6
312	One-lung ventilation to treat hepatic dome lesion $\hat{a}\in$ a further step towards minimally invasive surgery: a case report. Journal of Medical Case Reports, 2019, 13, 83.	0.4	6
313	The impact of liver resection on survival for locally advanced intrahepatic cholangiocarcinoma tumors: A propensity score analysis. European Journal of Surgical Oncology, 2020, 46, 632-637.	0.5	6
314	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer, 2021, 10, 126-136.	4.2	6
315	Circulating prostaglandin E2: a novel potential prognostic biomarker in patients with hepatocellular carcinoma. Clinical and Experimental Medicine, 2021, 21, 675-682.	1.9	6
316	Circulating MicroRNA-21 and MicroRNA-122 as Prognostic Biomarkers in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. Biomedicines, 2021, 9, 890.	1.4	6
317	Proof of Concept: Microinvasive AngioVac Approach in Renal Cell Carcinoma With Atrial Thrombosis. Annals of Thoracic Surgery, 2021, 112, e193-e196.	0.7	6
318	Administration of hepatic stimulatory substance alone or with other liver growth factors does not ameliorate acetaminophen-induced liver failure. Hepatology, 1993, 17, 429-33.	3.6	6
319	R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. JHEP Reports, 2022, 4, 100445.	2.6	6
320	Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy. Medicina (Lithuania), 2022, 58, 290.	0.8	6
321	Variations in riskâ€adjusted outcomes following 4318 laparoscopic liver resections. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 521-530.	1.4	6
322	Aminoguanidine inhibits the generation of nitric oxide in vitro and prolongs islet xenograft survival in rats. Transplantation Proceedings, 1997, 29, 2152-2153.	0.3	5
323	Physiological and clinical implications of proANP(1–98) circulating levels in the perioperative phase of liver transplantation. Clinica Chimica Acta, 2001, 310, 39-48.	0.5	5
324	Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation. Transplantation Proceedings, 2001, 33, 2258-2262.	0.3	5

#	Article	IF	CITATIONS
325	Pediatric Liver Transplantation: The University of Padua Experience. Transplantation Proceedings, 2007, 39, 1939-1941.	0.3	5
326	Cyclosporine pharmacokinetics and blood pressure responses after conversion to once-daily dosing in maintenance liver transplant patients. Clinical Transplantation, 2007, 22, 070806210014001-???.	0.8	5
327	A novel approach to severe acute pancreatitis in sequential liver-kidney transplantation: the first report on the application of VAC therapy. Transplant International, 2011, 24, e23-e27.	0.8	5
328	Survival Benefit of Transplantation for Recurrence of Hepatocellular Carcinoma After Liver Resection. Transplantation Proceedings, 2014, 46, 2287-2289.	0.3	5
329	Early circulatory complications in liver transplant patients. Transplantation Reviews, 2019, 33, 219-230.	1.2	5
330	Outcome of a First Episode of Bacterial Infection in Candidates for Liver Transplantation. Liver Transplantation, 2019, 25, 1187-1197.	1.3	5
331	Infrarenal versus supraceliac aorto-hepatic arterial revascularisation in adult liver transplantation: multicentre retrospective study. Updates in Surgery, 2020, 72, 659-669.	0.9	5
332	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opinion on Investigational Drugs, 2021, 30, 377-388.	1.9	5
333	Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation – a multicenter cohort study. Transplant International, 2021, 34, 743-753.	0.8	5
334	Thoracoscopic Ablation of Critically Located Liver Tumors: A Safety and Efficacy Cohort Study. Frontiers in Surgery, 2021, 8, 626297.	0.6	5
335	Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the SHELTER trial Journal of Clinical Oncology, 2013, 31, e15088-e15088.	0.8	5
336	Prognostic Factors for 10-Year Survival in Patients With Hepatocellular Cancer Receiving Liver Transplantation. Frontiers in Oncology, 2022, 12, 877107.	1.3	5
337	Algorithm for Prioritization of Patients on the Waiting List for Liver Transplantation. Transplantation Proceedings, 2007, 39, 1855-1856.	0.3	4
338	HCV Histological Recurrence and Survival Following Liver Transplantation in Patients With and Without Hepatocellular Carcinoma. Transplantation Proceedings, 2008, 40, 1974-1975.	0.3	4
339	Subjective Satisfaction and Quality of Life in Patients Prior to Listing for Liver Transplantation. International Journal of Artificial Organs, 2009, 32, 39-42.	0.7	4
340	Liver Resection Associated With Mini Porto-Caval Shunt as Salvage Treatment in Patients With Progression of Hepatocellular Carcinoma Before Liver Transplantation: A Case Report. Transplantation Proceedings, 2010, 42, 1378-1380.	0.3	4
341	Courage and representations of death in patients who are waiting for a liver transplantation. Cogent Psychology, 2017, 4, 1294333.	0.6	4
342	Video-laparoscopic MW ablation in a European high volume center: Safety and efficacy of 891 procedures. Digestive and Liver Disease, 2018, 50, 54-55.	0.4	4

#	Article	IF	CITATIONS
343	HCC recurrence in HCVâ€infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a <i>postâ€hoc</i> analysis. Transplant International, 2020, 33, 917-924.	0.8	4
344	Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study Journal of Clinical Oncology, 2012, 30, 4115-4115.	0.8	4
345	Molecular Refinement of Clinical Staging in Hepatocellular Carcinoma Patients Evaluated for Potentially Curative Therapies. PLoS ONE, 2011, 6, e23093.	1.1	4
346	SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. Biomarkers in Medicine, 2020, 14, 855-867.	0.6	4
347	Multimodal approach and its impact on survival for patients with hepatocellular carcinoma. Anticancer Research, 2003, 23, 4047-53.	0.5	4
348	Metabolic activity of rat hepatocytes cultured on homologous acellular matrix and transplanted into Gunn rats. International Journal of Molecular Medicine, 2006, 18, 837-42.	1.8	4
349	Liver Transplantation for Hepatocellular Carcinoma: Need for a New Patient Selection Strategy. Annals of Surgery, 2004, 240, 923-924.	2.1	3
350	CYTOCHINES AND LIVER FAILURE: MODIFICATION OF TNF-a AND IL-6 IN PATIENTS WITH ACUTE ON CHRONIC LIVER DECOMPENSATION TRETED WITH MOLECULAR ADSORBENT RECYCLING SYSTEM (MARS). Transplantation, 2004, 78, 739.	0.5	3
351	Laparoscopic Ablation and Salvage Transplantation in Patients with Hepatocellular Carcinoma. Transplantation, 2012, 94, 637.	0.5	3
352	Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma. Digestive and Liver Disease, 2012, 44, 361-362.	0.4	3
353	Liver Transplantation in Children With Congenital Cardiac Defects: AÂCase Report and a Short Literature Review. Transplantation Proceedings, 2013, 45, 2769-2773.	0.3	3
354	Liver resection is a therapeutic option for highly selected BCLC C patients in the context of an expert multidisciplinary setting. Digestive and Liver Disease, 2013, 45, 460-461.	0.4	3
355	Estimation of Liver Transplant Related Survival Benefit: the Devil Is in The Details. Gastroenterology, 2016, 150, 534-535.	0.6	3
356	Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?. Oncologist, 2019, 24, e77-e79.	1.9	3
357	mTOR pathway and somatostatin receptors expression intratumor-heterogeneity in ileal NETs. Endocrine-Related Cancer, 2021, 28, 449-456.	1.6	3
358	Administration of hepatic stimulatory substance alone or with other liver growth factors does not ameliorate acetaminophen-induced liver failure. Hepatology, 1993, 17, 429-433.	3.6	3
359	Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting. Alimentary Pharmacology and Therapeutics, 2020, 51, 482-483.	1.9	3
360	Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and "normal―liver tissues. PLoS ONE, 2020, 15, e0244356.	1.1	3

#	Article	IF	CITATIONS
361	Laboratory test scores to aid identification of primary nonfunction of liver transplants. Clinical Chemistry, 1995, 41, 471.	1.5	3
362	Early predictive markers of irreversible graft dysfunction after liver transplantation. Transplantation Proceedings, 1994, 26, 3599-601.	0.3	3
363	Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation. Transplant International, 2004, 17, 713-716.	0.8	2
364	Alcohol- and Substance-Dependent Subjects: The Correlated Factors in Qualifying for Liver Transplantation. Transplantation Proceedings, 2007, 39, 1861-1863.	0.3	2
365	479 THE RELATIONSHIP BETWEEN SEXUAL DYSFUNCTION, DEPRESSION AND QUALITY OF LIFE AMONG FEMALE BEFORE AND AFTER LIVER TRANSPLANTATION. Journal of Hepatology, 2009, 50, S180.	1.8	2
366	108 A NOVEL MODEL OF PRIORITY ASSESSMENT FOR PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA ON A COMMON LIVER TRANSPLANT WAITING LIST: A MULTICENTRE, COHORT STUDY. Journal of Hepatology, 2013, 58, S48.	1.8	2
367	P915 PREDICTION OF RECURRENCE AFTER LIVER TRANSPLANTATION FOR HCC: VALIDATION OF THE AFP MODEL IN AN ITALIAN COHORT. Journal of Hepatology, 2014, 60, S380.	1.8	2
368	Higher retransplantation rate following extended right splitâ€liver transplantation: An analysis from the eurotransplant liver followâ€up registry. Liver Transplantation, 2018, 24, 849-850.	1.3	2
369	Which Is the True Role of Bridging Therapies for HCC Patients Waiting for Liver Transplantation?. Annals of Surgery, 2018, 268, e56-e57.	2.1	2
370	Necroptosis is associated with a better survival in intrahepatic cholangiocarcinoma. Digestive and Liver Disease, 2019, 51, e2-e3.	0.4	2
371	Analysis of clinical course of portal vein thrombosis in cirrhosis with hepatocellular carcinoma. Digestive and Liver Disease, 2021, 53, S43.	0.4	2
372	NAFLD: a multi-faceted morbid spectrum with uncertain diagnosis and complicated management. Minerva Surgery, 2021, 76, 450-466.	0.1	2
373	Ante situm liver surgery using machine perfusion liver preservation: pilot human experience. British Journal of Surgery, 2021, 108, e235-e236.	0.1	2
374	Fulminant hepatic failure: the issue of patient selection for hazardous liver assistance. Transplantation Proceedings, 2000, 32, 2719-2722.	0.3	1
375	GH/GHBP changes in the perioperative course of liver transplantation: pathophysiologic and clinical implications. Transplantation Proceedings, 2001, 33, 1390-1392.	0.3	1
376	Histological features of donor grafts for orthotopic liver transplantation. Transplantation Proceedings, 2001, 33, 1177-1178.	0.3	1
377	Machine perfusion at 20°C as valid alternative for fatty liver graft preservation. Digestive and Liver Disease, 2007, 39, A37.	0.4	1
378	Reply: The easiest way to improve the outcome of suboptimal liver grafts. Liver Transplantation, 2008, 14, 906-907.	1.3	1

#	Article	IF	CITATIONS
379	Machine perfusion of fatty livers at 20° reduces sinusoidal cell and hepatocyte apoptosis respect to conventional cold storage. Digestive and Liver Disease, 2009, 41, A21-A22.	0.4	1
380	Benefit and harm of deceased- or living-donor liver transplantation for hepatocellular carcinoma. Digestive and Liver Disease Supplements, 2009, 3, 88-92.	0.2	1
381	788 INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA (HCC): TO TACE OR NOT TO TACE?. Journal of Hepatology, 2009, 50, S288-S289.	1.8	1
382	473 NON ADHERENCE TO MEDICAL PRESCRIPTIONS IN LIVER TRANSPLANTATION: A PROSPECTIVE LONGITUDINAL STUDY. Journal of Hepatology, 2010, 52, S191-S192.	1.8	1
383	Merging epidemiological changes and surveillance data to optimize management of hepatocellular carcinoma. Digestive and Liver Disease, 2011, 43, 841-842.	0.4	1
384	Cavoportal Hemitransposition Associated to Portoportal Anastomosis for Liver Transplant in Portomesenteric Thrombosis. Transplantation, 2013, 96, e69-e71.	0.5	1
385	Potential net health benefit of pre-transplant Sofosbuvir to prevent recurrence of HCV infection after liver transplantation: A multicenter, cohort model study. Digestive and Liver Disease, 2014, 46, e132-e133.	0.4	1
386	Representing Subnormothermic Machine Perfusion in Fatty Livers: The Complete Picture?. American Journal of Transplantation, 2017, 17, 1421-1422.	2.6	1
387	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicentre cohort study. Digestive and Liver Disease, 2017, 49, e4-e5.	0.4	1
388	P.04.7 PREVALENCE OF DE NOVO METABOLIC SYNDROME AND ITS RISK FACTORS IN A LIVER TRANSPLANTED POPULATION: A PROSPECTIVE STUDY. Digestive and Liver Disease, 2019, 51, e174.	0.4	1
389	Time-varying mHAP III is the most accurate score in predicting survival in patients with hepatocellular carcinoma (HCC) undergoing trans-arterial chemoembolization (TACE). Digestive and Liver Disease, 2019, 51, e6.	0.4	1
390	A Translational Approach to Standardization of Machine Perfusion Adoption in Ex Vivo Liver Resection. Annals of Surgical Oncology, 2020, 27, 1919-1919.	0.7	1
391	Unchanged surgical management of patients with Cholangiocarcinoma during the COVID-19 pandemic. Digestive and Liver Disease, 2020, 52, 944-945.	0.4	1
392	Role of a dedicated referral system for patients with liver disease and potential indication for liver transplantation: prospective data from a single centre experience. Digestive and Liver Disease, 2020, 52, e70-e71.	0.4	1
393	Recent trends and intention-to-treat survival of liver transplantation for nonalcoholic steatohepatitis: an Italian liver transplant registry study. Digestive and Liver Disease, 2020, 52, e16-e17.	0.4	1
394	Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?. Liver Cancer, 2021, 10, 1-2.	4.2	1
395	Videolaparoscopic MicroWave Ablation: An innovative technique to treat pancreatoblastoma liver metastases in children. Journal of Pediatric Surgery Case Reports, 2021, 69, 101876.	0.1	1
396	AF.79 EPIDEMIOLOGICAL TRENDS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH METABOLIC-DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN ITALY. Digestive and Liver Disease, 2021, 53, S173.	0.4	1

#	Article	IF	CITATIONS
397	Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma Journal of Clinical Oncology, 2012, 30, e14563-e14563.	0.8	1
398	Systemic therapies for hepatocellular carcinoma: a recap of the current status. Hepatoma Research, 2018, 4, 10.	0.6	1
399	Liver transplantation as last-resort treatment for patients with bile duct injuries following cholecystectomy: a multicenter analysis. Annals of Gastroenterology, 2020, 34, 111-118.	0.4	1
400	Laparoscopic and percutaneous microwave ablation to treat liver metastasis from colon cancer. A tool for long-term iterative strategy: results from a high volume center. Hpb, 2021, 23, S803-S804.	0.1	1
401	Traumatic complete transsection of the left hepatic duct: another approach to repair. The European Journal of Surgery, 2002, 168, 563-5.	1.0	1
402	Successful pregnancy in a liver transplant recipient treated with lamivudine for de novo hepatitis B in the graft. Transplant International, 2004, 17, 730-734.	0.8	0
403	Split-liver transplantation: A 10-year multicentre experience in an Italian transplant programme.  Digestive and Liver Disease, 2007, 39, A30.	0.4	0
404	Further data supporting machine perfusion ability to preserve steatotic rat livers: Role of kupffer and biliary epithelial cells. Digestive and Liver Disease, 2007, 39, A35-A36.	0.4	0
405	Compliance to medical regimen in patients before and after liver transplantation: Are there any predictive factors?. Digestive and Liver Disease, 2007, 39, A38-A39.	0.4	0
406	Predictors of unresectability in hepatoblastoma: A 20-year single centre report. Digestive and Liver Disease, 2007, 39, A69.	0.4	0
407	Molecular staging of HCC patients eligible for potentially radical therapies. Digestive and Liver Disease, 2008, 40, A12-A13.	0.4	0
408	Histological HCV recurrence after liver transplantation (LT): The impact of antiviral therapy on fibrosis progression. Digestive and Liver Disease, 2008, 40, A125-A126.	0.4	0
409	HCV RECURRENCE ON PROTOCOL LIVER BIOPSIES AFTER LIVER TRANSPLANTATION. Transplantation, 2008, 86, 427-428.	0.5	0
410	Preoperative diagnosis of poorly differentiated grade in patients with large hepatocellular carcinoma: A prospective controlled study. Digestive and Liver Disease, 2009, 41, A15.	0.4	0
411	The ethical equipoise in living and deceased donor liver transplantation: Towards decision processes based on mathematical models. Digestive and Liver Disease, 2009, 41, A16-A17.	0.4	0
412	USE OF N-ACETILCISTEIN DURING LIVER PROCUREMENT: FINAL REPORT OF A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL Transplantation, 2010, 90, 153.	0.5	0
413	PREDICTING THE TRANSPLANT BENEFIT IN PATIENTS WITH MULTI-NODULAR HEPATOCELLULAR CARCINOMA. ON BEHALF OF THE ITA.LI.CA STUDY GROUP Transplantation, 2010, 90, 779.	0.5	0
414	D-MELD PREDICTION OF GRAFT SURVIVAL AFTER DECEASED DONOR LIVER TRANSPLANTATION. RESULTS OF THE ITALIAN RETROSPECTIVE MULTICENTER DONOR-RECIPIENT MATCH STUDY Transplantation, 2010, 90, 171.	0.5	0

#	Article	IF	CITATIONS
415	MELD-Na and Survival Benefit in Liver Transplantation. Transplantation, 2012, 94, 677.	0.5	О
416	Can the Un-Sustainable Match Be Identified in Liver Transplant Population? Evidencies from the Italian Donor-2-Recipient D-Meld Study. Transplantation, 2012, 94, 567.	0.5	0
417	Outcome of liver transplantation in children under 10kg: Experience at a single Italian Tertiary Center (University of Padova, 1993–2012) and review of the literature. Digestive and Liver Disease, 2013, 45, e309.	0.4	0
418	Renal Function Deterioration Is Higher Within The First Year After Liver Transplantation: Results of The Italian Cross-Sectional, Multicenter Study (SURF) Transplantation, 2014, 98, 759-760.	0.5	0
419	Barcelona Clinic Liver Cancer staging and the net benefit of liver resection for patients with hepatocellular carcinoma: a multicentre, cohort study. Digestive and Liver Disease, 2014, 46, e15-e16.	0.4	0
420	Final results of the gideon study according to patient etiology: The italian experience. Annals of Oncology, 2015, 26, vi93.	0.6	0
421	Positive correlation of HIF2α and SERPINB3 in human hepatocellular carcinoma: selectivity and prognostic implications. Digestive and Liver Disease, 2015, 47, e41-e42.	0.4	0
422	P-110 Hepatocellular carcinoma in elderly patients: Final results of the Italian cohort of GIDEON study. Annals of Oncology, 2015, 26, iv31.	0.6	0
423	HCV eradication is not associated with drop-out due to HCC progression in patients awaiting liver transplantation: A monocentric experience. Digestive and Liver Disease, 2016, 48, e237.	0.4	0
424	Transition of pediatric liver transplanted recipients to Adult Healthcare Service: A single center cohort. Digestive and Liver Disease, 2016, 48, e61.	0.4	0
425	Prognostic relevance of stage migration in patients with hepatocellular carcinoma: A multicenter cohort study. Digestive and Liver Disease, 2016, 48, e9.	0.4	0
426	Validation of a method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common waiting list. Digestive and Liver Disease, 2016, 48, e22.	0.4	0
427	Laparoscopic ablation and salvage transplantation for patients with hepatocellular carcinoma.  Digestive and Liver Disease, 2016, 48, e24.	0.4	0
428	Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. Digestive and Liver Disease, 2016, 48, e37.	0.4	0
429	Terlipressin given by continuous intravenous infusion vs terlipressin given by intravenous boluses in the treatment of hepatorenal syndrome in patients with cirrhosis: Final results of a controlled clinical study. Digestive and Liver Disease, 2016, 48, e15.	0.4	0
430	The protease-inhibitor SerpinB3 modulate survival and Wnt pathway of inflammatory human monocytes. Digestive and Liver Disease, 2016, 48, e27.	0.4	0
431	Liver Retransplantation for Hepatic Abscess Due to Hepatic Artery Thrombosis: A Case Report. Transplantation Proceedings, 2017, 49, 736-739.	0.3	0
432	Outcome of liver transplant recipients after the first episode of bacterial infection. Digestive and Liver Disease, 2017, 49, e12.	0.4	0

#	Article	IF	Citations
433	Eradication of HCV in patients awaiting liver transplantation does not increase drop-out due to HCC progression. Digestive and Liver Disease, 2017, 49, e47.	0.4	0
434	Evolution of liver transplantation for alcoholic liver disease: A single center study. Digestive and Liver Disease, 2017, 49, e240.	0.4	0
435	Reply. Liver Transplantation, 2017, 23, 1630-1631.	1.3	0
436	Bridging therapies are not detrimental in patients with hepatocellular cancer waiting for liver transplant: A propensity score analysis. Digestive and Liver Disease, 2018, 50, 7-8.	0.4	0
437	Liver resection for benign disease: have the indications increased in the era of minimally invasive approach? An IGoMILS-based study. Hpb, 2018, 20, S439.	0.1	0
438	The Efficacy of CMV Specific Immune Reconstitution is Highly Dependent on Donor/Recipient Serostatus and Type of Solid Organ Transplanted. Transplantation, 2018, 102, S334.	0.5	0
439	The survival benefit of hepatic resection in advanced cases for intrahepatic cholangiocarcinoma: a surveillance, epidemiology and end results (SEER) analysis. Journal of Hepatology, 2018, 68, S375-S377.	1.8	0
440	Efficacy and safety of Niuliva $\hat{A}^{\otimes}$ immune globulin to prevent hepatitis B reinfection in $\hat{A}$ de novo orthotopic liver transplant. Future Virology, 2019, 14, 85-94.	0.9	0
441	The role of alcoholic liver disease as risk factor for the development of de novo metabolic syndrome after liver transplantation: a prospective longitudinal study. Digestive and Liver Disease, 2019, 51, e51.	0.4	0
442	Development of a model based on case-mix analysis to predict 6-month patient survival after liver transplantation: a multicenter Italian study. Digestive and Liver Disease, 2019, 51, e11-e12.	0.4	0
443	Laparoscopic liver resection versus transarterial chemoembolization for hepatocellular carcinoma in child B cirrhosis: a propensity score analysis. Digestive and Liver Disease, 2019, 51, e52.	0.4	0
444	De novo neoplasms after liver transplantation: donor gender and age influence. Digestive and Liver Disease, 2019, 51, e50.	0.4	0
445	Preface. Transplantation Proceedings, 2019, 51, 95.	0.3	0
446	An intention-to-treat competing-risk model for candidates with hepatocellular cancer waiting for liver transplantation. Digestive and Liver Disease, 2019, 51, e13.	0.4	0
447	Outcome of critically ill patients with cirrhosis and ACLF after ICU admission. Digestive and Liver Disease, 2019, 51, e14.	0.4	0
448	Laparoscopic liver resection versus transarterial chemoembolization for hepatocellular carcinoma in child B cirrhosis: a propensity score analysis. Hpb, 2019, 21, S1006-S1007.	0.1	0
449	Liver resection for hilar cholangiocarcinoma in patients over 70 years: does preoperative cholangitis exclude older patients from surgery?. Hpb, 2019, 21, S551-S552.	0.1	0
450	Society of Organ and Tissue Transplantation 2018. Transplantation Proceedings, 2019, 51, 2855.	0.3	0

#	Article	IF	CITATIONS
451	Risk adjusted benchmarks in laparoscopic liver surgery: Data from the Italian group of minimally invasive liver registry. Hpb, 2020, 22, S386-S387.	0.1	O
452	Reassessment of the risk of recurrence (R3) after liver transplantation for HCC: validation of the R3 v.2 score and comparison with existing models: results of a multinational analysis in 2,444 patients. Journal of Hepatology, 2020, 73, S9-S11.	1.8	О
453	The concept of time-varying therapeutic hierarchy for patients with hepatocellular carcinoma: a multicenter cohort study. On behalf of the ITA.LI.CA study group. Journal of Hepatology, 2020, 73, S99-S100.	1.8	O
454	OC.05.1 MICRORNA-21 AND MICRORNA-122: PROGNOSIS PREDICTION AND CORRELATION WITH HIF-1ALPHA IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH TRANSARTERIAL CHEMOEMBOLIZATION. Digestive and Liver Disease, 2020, 52, S17-S18.	0.4	O
455	De novo metabolic syndrome after liver transplantation: a prospective, longitudinal study. Journal of Hepatology, 2020, 73, S253-S254.	1.8	o
456	Prognostic and diagnostic role of angiogenesis biomarkers in hepatocellular carcinoma treated with chemoembolization. Journal of Hepatology, 2020, 73, S378-S379.	1.8	0
457	Adherence to Surviving Sepsis campaign 3-hour bundles improves survival in non-critically ill patients with cirrhosis and sepsis. Digestive and Liver Disease, 2020, 52, e12-e13.	0.4	O
458	Pregnancy after liver transplantation: a survey from Italian liver transplants centres. Digestive and Liver Disease, 2021, 53, S12-S13.	0.4	0
459	Increased platelet aggregation in patients with cirrhosis and hepatocellular carcinoma: A new potential therapeutic target?. Digestive and Liver Disease, 2021, 53, S37-S38.	0.4	O
460	Liver Transplantation during the COVID-19 pandemic: A quantitative model balancing individual patient benefit against population healthcare needs. Digestive and Liver Disease, 2021, 53, S44.	0.4	0
461	A Novel Entity Among Vascular Liver Tumors: The First Reported Liver Transplantation. Is It Feasible?. Transplantation Proceedings, 2021, 53, 1690-1693.	0.3	O
462	OC.04.8 IMPACT OF COVID-19 PANDEMIC ON REFERRAL OF PATIENTS WITH LIVER DISEASE TO A LIVER TRANSPLANT CENTER. Digestive and Liver Disease, 2021, 53, S109.	0.4	0
463	OC-04Epidemiological trends of hepatocellular carcinoma in patients with Metabolic-Dysfunction-Associated Fatty Liver Disease in Italy Digestive and Liver Disease, 2021, 53, S2.	0.4	O
464	Posterior Right Disconnected Bile Duct. , 2017, , 235-244.		0
465	Benefits of Laparoscopy for Major Liver Resection in Cirrhotic Patients: Time for Pushing Indications Beyond the Limits? A Propensity Score Matched Analysis. Hpb, 2021, 23, S746-S747.	0.1	O
466	Minimally-invasive Stage 1 to Protect against the Risk of Liver Failure in ALPPS for Hepatocellular Carcinoma. Hpb, 2021, 23, S725-S726.	0.1	0
467	Textbook Outcome in Laparoscopic and Open Liver Surgery (TOLS): An International Multicenter Analysis of 8188 Patients. Hpb, 2021, 23, S734.	0.1	O
468	Cooling Techniques and Ex Situ Liver Surgery. Updates in Surgery Series, 2020, , 29-39.	0.0	0

#	Article	IF	CITATIONS
469	Left Split Liver. Updates in Surgery Series, 2020, , 97-106.	0.0	O
470	Small-for-Size Syndrome. Updates in Surgery Series, 2020, , 123-137.	0.0	0
471	Different Impact of Positive Radial Margin and Ductal Margin on Recurrence and Survival in Perihilar Cholangiocarcinoma. Hpb, 2021, 23, S685-S686.	0.1	0
472	Technical Refinements to the RAPID Technique: A Potential Breakthrough in Transplant Oncology. Hpb, 2021, 23, S704-S705.	0.1	0
473	OC.05.6 GENDER-RELATED DIFFERENCES IN SCCA-IGM LEVELS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH TRANSARTERIAL CHEMOEMBOLIZATION. Digestive and Liver Disease, 2020, 52, S20-S21.	0.4	0
474	Liver transplantation. A summary of our surgical practice. Chirurgia Italiana, 1999, 51, 9-14.	0.2	0
475	Impact of bacterial infections prior liver transplantation on post-transplant outcomes in patients with cirrhosis. Digestive and Liver Disease, 2022, 54, S26-S27.	0.4	0
476	Diagnostic and prognostic role of urinary Neutrophil Gelatinase-associated Lipocalin in patients with cirrhosis and acute kidney injury. Digestive and Liver Disease, 2022, 54, S8.	0.4	0
477	SARS-CoV-2 infection in liver transplantation is associated with favorable outcomes: an Italian transplant registry study. Digestive and Liver Disease, 2022, 54, S14.	0.4	0
478	Development and validation of a deep learning model for the prediction of hepatocellular cancer recurrence after transplantation: an international study. Digestive and Liver Disease, 2022, 54, S9.	0.4	0
479	Prognostic Models predicting allograft failure at 90 and 365 days after liver transplantation. Call for an international Est to West prospective observational study to guide re-transplantation. Digestive and Liver Disease, 2022, 54, S10.	0.4	0
480	Role of immune activation and senescent profile as prognostic markers for cancer onset in patients undergoing liver transplantation. Digestive and Liver Disease, 2022, 54, S4.	0.4	0
481	Title is missing!. , 2020, 15, e0244356.		0
482	Title is missing!. , 2020, 15, e0244356.		0
483	Title is missing!. , 2020, 15, e0244356.		0
484	Title is missing!. , 2020, 15, e0244356.		0
485	Development and validation of a deep learning model for the prediction of hepatocellular cancer recurrence after transplantation: An international study. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S71-S71.	0.1	0